VivoSim Labs (VIVS) Stock Price, News & Analysis

Company Overview

Organovo Holdings, Inc., a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture. The company offers ExVive human liver tissue and ExVive human kidney tissue used for predictive preclinical testing of drug compounds. It is also developing in vivo liver tissues to treat end-stage liver, life-threatening, and orphan diseases. The company was incorporated in 2007 and is headquartered in Solana Beach, California.

Key Stats

• Today's Range: $1.43 to $1.48
• 50-Day Range: N/A
• 52-Week Range: $1.41 to $21.96
• Volume: 41,915 shs
• Average Volume: 58,209 shs
• Market Capitalization: $3.80 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

VIVS Stock Analysis - Frequently Asked Questions

How have VIVS shares performed this year?

VivoSim Labs' stock was trading at $1.91 at the beginning of 2025. Since then, VIVS stock has decreased by 23.6% and is now trading at $1.46.
View the best growth stocks for 2025 here.

How do I buy shares of VivoSim Labs?

Shares of VIVS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Today: 6/22/2025
• Fiscal Year End: 3/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:VIVS
• CIK: 1497253
• Web: N/A
• Phone: (858) 224-1000
• Fax: N/A
• Employees: 20
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($10.20)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$2.48 million
• Net Margins: -1,725.00%
• Pretax Margin: -1,726.39%
• Return on Equity: -46.87%
• Return on Assets: -28.62%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 3.25
• Quick Ratio: 3.25

Sales & Book Value

• Annual Sales: $140 thousand
• Price / Sales: 27.11
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $5.54 per share
• Price / Book: 0.26

Miscellaneous

• Outstanding Shares: 2,600,000
• Free Float: 2,503,000
• Market Cap: $3.80 million
• Optionable: N/A
• Beta: 1.03